Main menu

Recent Pfizer Press Releases

7/7/14 4:36pm EDT
CliniWorks Forms a Strategic Alliance with Pfizer to Develop a Population Health Management Platform with Advanced Analytics and Patient Care Capabilities

CliniWorks announced a strategic alliance between its Israeli subsidiary CliniWorks (Israel) Ltd. (“CliniWorks Israel”) and Pfizer Inc. (“Pfizer”) to jointly advance the parties’ respective capabilities in working with healthcare provider organizations to identify and close clinical or quality gaps to improve population health.

more...
7/1/14 12:00pm EDT
Pfizer Inc. Receives Kosher Certification for Elelyso™ (taliglucerase alfa) for Injection, for the Treatment of Type 1 Gaucher Disease

Treatment for rare inherited lysosomal storage disorder is the first prescription medication to receive kosher certification from the Orthodox Union

Pfizer Inc. (NYSE:PFE) today announced that the Orthodox Union (OU) has granted kosher certification to ELELYSO™ (taliglucerase alfa) for injection, an enzyme replacement therapy (ERT) for the long-term treatment of adults with a confirmed diagnosis of Type 1 Gaucher disease. ELELYSO is the first prescription medication to be certified kosher by the OU, a milestone for the brand which was approved by the U.S. Food and Drug Administration (FDA) in May 2012.

more...
6/26/14 11:20am EDT
Pfizer Declares 26-Cent Third-Quarter 2014 Dividend

The board of directors of Pfizer Inc. today declared a 26-cent third-quarter 2014 dividend on the company’s common stock, payable September 3, 2014, to shareholders of record at the close of business on August 1, 2014.

more...
6/26/14 9:45am EDT
James C. Smith Elected to Pfizer’s Board of Directors

 

Pfizer Inc. today announced the election of James C. Smith to its Board of Directors, effective immediately. Mr. Smith also was appointed to the Corporate Governance and Science and Technology Committees of Pfizer’s Board.

more...
6/24/14 10:00am EDT
Pfizer Invites Public to View and Listen to Webcast of July 29 Conference Call with Analysts

 

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 29, 2014. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2014 Performance Report, to be issued that morning.

more...
6/20/14 9:54am EDT
Prevenar 13® Indication Extended in Japan

 

Adults 65 or older can now be immunized with the same Pneumococcal Conjugate Vaccine used in children.

6/18/14 5:01pm EDT
Two-Year Results From Pfizer’s XELJANZ® (Tofacitinib Citrate) ORAL Start Study Published in The New England Journal of Medicine

 

Phase 3 Study ORAL Start Showed XELJANZ Monotherapy Superior to Methotrexate in Inhibiting the Progression of Structural Damage and Reducing Signs and Symptoms of Rheumatoid Arthritis in Methotrexate-Naïve Patients

Findings Contribute to Growing Body of Evidence Supporting Efficacy and Safety Profile of XELJANZ as Monotherapy in Rheumatoid Arthritis

Pfizer Inc. (NYSE:PFE) announced today the publication of two-year results from the ORAL Start study in the June 19 issue of The New England Journal of Medicine.

more...
6/18/14 1:00am EDT
Pfizer And Cellectis Enter Into Global Strategic Cancer Immunotherapy Collaboration

 

Collaboration to Utilize Cellectis’ Proprietary Allogeneic CAR-T Platform Technology to Develop Immunotherapies Against Select Targets in the Field of Oncology

Pfizer Inc. (NYSE:PFE) and Cellectis (Paris:ALCLS) today announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets. Cellectis’ CAR-T platform technology provides a proprietary, allogeneic approach (utilizing engineered T-cells from a single donor for use in multiple patients) to developing CAR-T therapies that is distinct from other autologous approaches (engineering a patient’s own T-cells to target tumor cells).

more...
6/17/14 8:00am EDT
Pfizer Announces Submission of Biologics License Application to the FDA for Investigational Meningococcal B Vaccine

Pfizer Inc. (NYSE:PFE) announced today that it has submitted a Biologics License Application (BLA) to the U.S.

more...
6/16/14 8:00am EDT
Pfizer Opens New State-of-the-Art Research and Development Site in Cambridge, Massachusetts

 

Bio-Innovation Hub Represents Significant Step in Pfizer’s Long-Standing Commitment to the Area

Pfizer Inc. (NYSE:PFE) announced today the opening of a new 280,000 square-foot Research and Development (R&D) hub in Cambridge, Mass. The new Pfizer facilities in Kendall Square bring together 1,000 colleagues from three area locations and position Pfizer in closer proximity to leading academic institutions, hospitals and patient organizations.

more...
6/11/14 8:00am EDT
Pfizer Announces Over 10 Abstracts for XELJANZ® (Tofacitinib Citrate) in Rheumatoid Arthritis to be Presented at the European League Against Rheumatism (EULAR) 2014 Annual Meeting

 

Additional Data Further Characterizes the Safety Profile of XELJANZ

Pfizer Inc. announced today that over 10 abstracts have been accepted for presentation at the European League Against Rheumatism (EULAR) 2014 Annual Meeting (June 11-14, Paris, France), seven of which are focused on further characterizing the safety profile of XELJANZ (tofacitinib citrate) in treating moderately to severely active rheumatoid arthritis.

more...
5/29/14 11:14am EDT
Dr. Morris J. Birnbaum Joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research

Pfizer Inc. announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research. He will report directly to Rod MacKenzie, Ph.D., Group Senior Vice President and Head of PharmaTherapeutics Research & Development, and will be based in a key Pfizer R&D hub in Cambridge, MA.

more...
5/29/14 8:00am EDT
Pfizer and the Avon Foundation for Women Announce $1 Million Grants Program to Address Gaps in Support for People Living with Metastatic Breast Cancer

·        New National Survey Reveals Lack of Public Knowledge About Metastatic Breast Cancer,1 which Currently Affects Up to 250,000 in the U.S.2

·        Innovative Partnership Will Fund New Projects Focused on Increasing Public Understanding, Enhancing Patient Support

 

 

Despite the high level of public attention devoted to breast cancer awareness, more than 60 percent of respondents in a new national survey commissioned by Pfizer Inc. say they know little to nothing about metastatic breast cancer.1

more...
5/27/14 8:30am EDT
Pfizer Brings Frequent Heartburn Relief Over-the-Counter with New Nexium® 24HR

The nation’s most prescribed acid blocker brand is now available without a prescription at retailers nationwide

Pfizer Inc. (NYSE: PFE) today announced the introduction in the U.S.

more...
5/26/14 10:02am EDT
ANNOUNCEMENT REGARDING ASTRAZENECA PLC

Statement from Pfizer Inc.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

more...
5/23/14 9:13am EDT
Pfizer Announces Detailed Results For Phase 3 OPT Retreatment Study Of Tofacitinib In Adults With Moderate-To-Severe Chronic Plaque Psoriasis

Findings Presented During 11th European Academy of Dermatology and Venereology Spring Symposium in Belgrade, Serbia

Pfizer Inc. (NYSE:PFE) announced today detailed results from the Oral treatment Psoriasis Trial (OPT) Retreatment study (A3921111), a Phase 3 study investigating tofacitinib for the treatment of adult patients with moderate-to-severe chronic plaque psoriasis.

more...
5/21/14 8:15am EDT
New Survey Highlights The Impact Of Menopausal Symptoms On Women In The Workplace

Key Findings Show What Many Are Doing to ‘Keep Their Cool’

A new national survey released today by Working Mother Media and Pfizer (NYSE:PFE) on the impact of menopausal symptoms on women in the workplace finds that managing menopausal symptoms in their work life is extremely or somewhat difficult for nearly half (48 percent) of working women ages 45-65 who have experienced these symptoms in the past year.

more...
5/19/14 6:41pm EDT
Statement from Pfizer Inc.

FINAL PROPOSAL TO ASTRAZENECA

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

19 May 2014

more...

Pages